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Screening for lung cancer with low radiation dose CT is effective if offered to people at increased risk 
of the disease. Target populations can be defined by multivariable models that predict risk. Two 
externally validated models, the Liverpool Lung Projectv2 (LLPv2) and the Prostate Lung Colorectal and 
Ovarianm2012 PLCOm2012 are recommended to select participants for the National Health Service targted 
Lung Health Check programme in England. Currently, direct contact with potential participant is 
required to obtain data for the models. A way to reduce the number of ineligible people contacted 
might be to apply the models directly to digital primary care data but how the models perform in this 
setting is not known. 
Method 
The Clinical Practice Research Datalink (CPRD), a computerised, longitudinal primary care database, 
was used to test both of the models. Lung cancer occurrence over 5 or 6 years was measured in a 
cohort aged 50 to 80 years of ever smokers and compared with the predictied risk over 5 years (LLPv2) 
and 6 years (PLCOm2012).  
Results 
Over 5 and 6 years there were 7123 and 7876 lung cancers respectively from a cohort of 834986. After 
recalibration of the model intercept, LLPV2 produced a c-statistic of 0.700 (0.694 to 0.710). Calibration 
plots showed an under-prediction of lung cancer cases at the lowest risk scores, followed by an over 
prediction (overall mean predicted risk of lung cancer 4.61%, actual risk of 0.9%). After imputing 
missing BMI and smoking intensity values, PLCOm2012 produced a c-statistic of 0.679 (0.673 – 0.685) in 
CPRD data. PLCOm2012 also over-estimated risk (mean predcited risk: 3.76%). Setting thresholds at <1% 
for LLP and < 0.15% for PLCO,  15.6 and 11.4% of ever smokers who developed lung cancer would not 
have been contacted for screening eligibility assessment, however this also avoids contacting 46% and 
34.5% of the cohort. 
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Conclusion  
Two validated multivariable models show only moderate discrimination when applied to routinely 
collected primary care data restricted to ever smokers aged 50 to 80 years, which may be explained 
by the quality and completeness of the data.  However, they may be used as a way to substantially 
reduce the total number of people who are contacted as part of a screening programme accepting 
that 10-15% of ever-smoking people aged 50 to 80 years who develop lung cancer may not have the 
chance to be evaluated for screening eligibilty. This will be an important consideration in health 
economic analyses. Further work is needed to establish to what extent newer models can improve on 




Randomised controlled trials have shown that screening with low dose computed tomography (LDCT) 
reduces lung cancer mortality.(1-3) Many countries are therefore planning implementation but 
questions remain around how to identify the population most likely to benefit. Most lung cancer 
screening trials used age and smoking pack year criteria to select participants.However, since the 
publication of the National Lung Screening Trial (NLST), further analyses have demonstrated that 
substantial variations in risk exist within trial populations.(4) Risk prediction models have been 
suggested to select eligible participants at high risk of lung cancer and have been shown to be more 
sensitive and specific compared with  using age and smoking history alone.(5-10) This may be due in 
part to these models incorporating more detailed smoking data and considering other risk factors such 
as chronic obstructive pulmonary disease (COPD) or asbestos exposure. The United Kingdom Lung 
Screening Trial (UKLS) used a multi-factorial risk prediction model (Liverpool Lung Project Version 2 – 
LLPV2) to select patients. (11, 12) The results of the UKLS showed that the proportion of patients in 
whom lung cancer was detected was similar in a single screening round to that achieved by three 
annual rounds in the NLST. However, the trade-off of selecting higher risk groups is that only a small 
proportion of the total population at risk of lung cancer is included and there is potential for those 
selected to be at greater risk of competing causes of death. To maximise the impact of a screening 
programme, models with better sensitivity and specificity are needed to ensure the greatest number 
of eligible people benefit whilst reducing the number of LDCTs required. As well as being accurate, 
models for use on a whole population need simple methods of data collection, or must use existing 
high-quality data.  
In the United Kingdom (UK) primary care records have been used to identify ever smokers for further 
risk stratification are a way to limit the number of approaches that have to be make to cover the target 
population.(13, 14) Although, inevitably, a small proportion may be missed, a much larger proportion 
of ineligible people are not approached and with less inconvenience, worry and cost. UK pilots have 
used both the LLPv2, at a threshold of either 2.5% or 5%, and the Prostate Lung Colorectal and Ovarian 
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(modified 2012) (PLCOm2012) at a threshold of 1.51%. An earlier version of this model was used to select 
subjects for the Pan-Canadian Early Detection of Lung Cancer (PanCan) study.(7) The UK pilots found 
baseline cancer rates of 2-3% and the PanCan study 5%.(5) The National Health Service (NHS) England 
Lung Health Check targeted screening programme has therefore recommended using either a 
PLCOm2012 6-year risk-threshold for lung cancer of 1.51% and/or an LLPv2 5-year risk-threshold of 2.5% 
to define eligibility, but these risk models have not been validated or calibrated in primary care data. 
Previous external validations have compared models in well-defined data derived from screening 
trials.(15, 16) A recent “real-world” UK pilot screening programme found that the PLCOm2012 model 
performed much as expected, although the investigators found some degree of miscalibration.(17) 
However, their population had received screening, which may partly account for this miscalibration. 
It is therefore important to understand whether models used in selection can be used in routinely 
collected primary care data of non-screened individuals and to establish the most appropriate risk 




DATA SOURCE  
We used data from the Clinical Practice Research Datalink (CPRD), a computerised, longitudinal 
primary care database, linked to a range of other health related data to provide a representative UK 
population health dataset. The data encompass 50 million patients, including 14 million who are 
currently registered. (18) All symptoms, medical diagnoses, prescriptions, investigations and results 
are entered into the computer system either during a consultation with a general practitioner (GP) or 
following communication from other healthcare providers.  
PATIENT DATA 
A general population cohort ≥ 40 years of age who were registered and contributing data for at least 
12 months between 1st January 2000 and 31st December 2015 was extracted from CPRD. Patients ≥ 40 
years of age who were diagnosed with lung cancer during this timeframe were identified from this 
cohort. To ensure that these were incident rather than prevalent cases, we excluded patients who 
registered less than 12 months prior to their diagnosis date. Data for English patients were linked to 
Cancer Registry data which provided additional information, including lung cancer pathological 
subtype and stage at diagnosis.  
LUNG CANCER PREDICTION MODELS 
This study externally validates two lung cancer prediction models: the LLPv2 and the PLCOm2012.(5, 8, 
19) CPRD data were used to identify and categorise the required variables to fit the models and derive 
a risk score for 5-year (LLPv2) and 6–year (PLCOm2012) risk score for lung cancer respectively. Personal 
history of pneumonia, COPD, smoking status, any cancer and family history of cancer were identified 
using medical code lists. Asbestos exposure is not routinely available in CPRD and to avoid bias by 
assuming that all patients were not exposed to asbestos, we searched CPRD for medical codes 
indicating ‘asbestosis’.(20) Data on ethnicity and education were not available so we assumed all 
patients to be white and have basic education (i.e. assuming normal secondary school completion in 
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the UK approximates to completing high school in the US). Additional CPRD files were used to extract 
data on body mass index (BMI). LLPv2 incorporates age at lung cancer diagnosis for a first degree 
relative, however details on the type of cancer in family members and age at diagnosis are not 
routinely collected in CPRD and therefore any lung cancer in a first degree relative was considered to 
be early onset (age <60). Models were also assessed with this variable excluded. 
SMOKING DATA IN CPRD 
Unlike trial data which record detailed individual smoking data at the time of a risk assessment, 
smoking data in CPRD are recorded whenever the person visits the GP. The GP records the details 
using medical and Read codes to indicate a patient’s smoking status; current, ex or never, and the 
intensity of smoking in categories. These categories are defined as: 1) very heavy smoker 40+ cig/day, 
2) heavy smoker 20-40 cig/day, 3) moderate smoker 10-19 cig/day, 4) light smoker 1-9 cig/day, 5) 
trivial smoker <1 cig/day and 6) smoker quantity unknown. In the PLCOm2012 model, smoking intensity 
is fitted as a continuous variable (7) so in order to fit the model we had to convert the categorical 
variable to a specific number of cigarettes smoked per day. Therefore we assumed very heavy smokers 
to have smoked 40 cig/day, heavy smokers 20 cig/day, moderate smokers 10 cig/day, light smokers 5 
cig/day and trivial smokers to have smoked 2 cig/day. Patients with missing smoking data throughout 
their follow up were considered to be never smokers. 
Only 10% of the population who were categorised as ever smokers had a documented age of starting 
smoking. Based on published literature, we assumed the age at which people started smoking to be 
18 years, which also coincides with the legal age to buy cigarettes in UK from 2007 (21-23). Sixty eight 
per cent of ex-smokers had a date of smoking cessation recorded in the additional CPRD files. Median 
day difference between smoking cessation date and the risk assessment date was calculated and 
substituted for 32% of the ex-smokers with missing date of smoking cessation. 
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DATA SETUP 
LLPv2 and PLCOm2012 predict 5 and 6 year lung cancer incidence respectively. We calculated 5- and 6-
year risk scores for all CPRD patients registered on 1st January 2009. We looked at 5 year incidence of 
having lung cancer for LLPv2 model, i.e. until 31st December 2013; and 6 year incidence of having lung 
cancer for PLCOm2012 model, i.e. until 31st December 2014. Lung cancer screening is unlikely to be 
offered to people aged below 50 years or above 80 years based on current modelling: therefore we 
excluded people aged <50 years or >80 years at the point of the risk assessment (1st January 2009). 
Similarly lung cancer screening is unlikely to be offered to never smokers and so only ever0-smokers 
were included in the cohort. This resulted in 842,109 individuals in our CPRD cohort. 
STATISTICAL ANALYSIS AND MULTIPLE IMPUTATION 
All data management and statistical analysis were performed using STATA version 16 (StataCorp) and 
the study was conducted and reported in line with the Transparent Reporting of a multivariate 
prediction model for Individual Prediction or Diagnosis (TRIPOD) guidelines (24). Occurrence of lung 
cancer was treated as a binary outcome at 5 years for LLP and 6 years for PLCOm2012. Distributions of 
demographic variables between lung cancer patients and non-lung cancer patients were evaluated. 
All patients actively participating in CPRD on 1st January 2009 were used to assess the performance of 
LLP (n=842,109). Multiple imputation by chained equation (MICE), to replace missing data on BMI 
(10%) and smoking quantity (28%), was performed based on all candidate predictors before applying 
the PLCOm2012 model. We created 5 imputed datasets for our cohort and combined them using Rubin’s 
rule to obtain final model estimates.(25) On the basis of the most conservative figure of 4,115 lung 
cancer events (exclusion of all possible duplications) during the six year post risk assessment and 
eleven risk predictors in PLCOm2012, we had a sample size of 374 lung cancer diagnoses per predictor, 
well above the minimum requirement of 10 events per predictor suggested by Peduzzi et al (26).  
We compared the demographics of the CPRD derived dataset with that of the original development 
sets for the LLP and PLCOm2012.(7, 19) 
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We assessed the performance of the models in terms of discrimination and calibration plots. (6, 27). 
The area under the receiver operating curve (AUC) was used to assess discrimination, ranging from 
0.5 indicating no discrimination to 1.0 indicating perfect discrimination. ‘Pmcalplot’ package on STATA 
was used to plot observed and predicted risk probabilities. We also assessed the performance of 
models by risk-thresholds and calculated the number needed to screen to identify 1 lung cancer 
patient based on those risk-threshold figures. For the LLPv2 model the risk-quartiles were set at risks: 
<1%, 1% to <2.5%, 2.5% to <5% and 5% or greater, while for PLCOm2012, our cohort was divided into 
risk tertiles of risks: <0.15%, 0.15% to 1.5% and greater than 1.5%. The values of the considered risk 
thresholds for the two models differ, as the models differ in absolute risk estimates due to differences 
in risk-levels between their development datasets. For comparision we also calculated AUCs for each 
model using data from NLST and PLCO. 
ETHICAL APPROVAL 
Approval for use of data for this project was granted by the CPRD Independent Scientific Advisory 
Committee (ISAC) (Protocol numbers 18_223 and 20_014R).   
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RESULTS 
STUDY PARTICIPANTS AND COMPARISON WITH ORIGINAL MODELS 
We analysed data on all (n=5,997,270) people actively contributing to CPRD between 1st January 2000 
and 31st December 2015. Lung cancer incidence was 85.8 per 100,000 person-years. The overall 
incidence was higher for men compared with women (98.5 vs 73.4 per 100,000 person-years). People 
aged between 50 and 80 years who were ever smokers were selected to form the validation 
population for LLPV2 and PLCOm2012 models. This comprised 842,109 participants. An overview of the 
demographics / model characteristics of the LLPV2 and PLCOm2012 cohorts and the CPRD cohort is 
presented in Tables 1a and 1b. Complete information for all risk factors was available for 100% of the 
population for LLPV2 validation but only 66% had complete information for PLCOm2012, mainly due to 
missing data on BMI and smoking intensity.  
CPRD COHORT AND ORIGINAL LLP COHORT DEMOGRAPHIC COMPARISON  
The median age of the lung cancer patients was higher in the CPRD cohort compared with LLP (69 
years vs 66 years respectively) and the median age of controls was lower in CPRD compared with LLP 
(61 years vs 66 years).(19) The CPRD group also had a higher proportion of female lung cancer cases 
compared with LLP (43% vs 38%). Even using a more inclusive definition of family history of any cancer 
and asbestosis as a surrogate for asbestos exposure, patients identified with those risk factors in CPRD 
were limited (family history of any cancer in CPRD = 0.1% vs LLP cohort = 21% and asbestosis in CPRD 
= <1% vs asbestos exposure in LLP cohort = 35% in cases). The full comparison is provided in Table 1a. 
CPRD COHORT AND PLCOm2012 COHORT DEMOGRAPHIC COMPARISON 
The PLCOm2012 model used information on 80,672 participants from the PLCO study who were ever 
smokers. Lung cancer cases in CPRD were older than both the NLST and PLCO groups (median age 69 
years vs 64 years and 65 years respectively).(7) Ten per cent of the BMI data was missing in CPRD 
patients (Table 1b), but the median BMI was the same for cases and controls for all of the cohorts. 
CPRD patients also had a low recording of family history or previous personal history of malignant 
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cancer compared with NLST and PLCO cohorts, reflecting the poor recording of family level data in 
primary care records. Twenty seven per cent of NLST participants had a self-reported history of COPD, 
which was more than both CPRD and PLCO cohorts (22% and 20% respectively). Data on ethnicity and 
education status were not routinely recorded at the time of data extraction in CPRD data, so they are 
not provided in Table 1b. Only 19% of non-lung cancer participants in PLCO were current smokers 
compared with 43% in CPRD and 47/ 48% in the NLST CT and CXR arms. A detailed comparison of 
smoking data between the cohorts is provided in Table 1b. 
COMPARISION OF RISK PREDICTION MODEL PERFORMANCE IN CPRD 
LLPV2  
In CPRD, 7123 lung cancer events took place in 5 years between 1st January 2009 and 31st December 
2013. The original LLPV2 model, which included never smokers, produced a c-statistic of 0.70 in 10-fold 
cross validation.(19) After recalibration of the model intercept, the external validation of LLPV2 
produced a c-statistic of 0.700 (0.694 to 0.710) in CPRD data (Table 2). The calibration plot of the 
recalibrated model is shown in Figure 1. There was an under-prediction of lung cancer cases at the 
lowest risk scores, followed by an over prediction. The overall mean predicted risk of lung cancer 
patients in the CPRD cohort was 4.61%. This compares with the actual risk of 0.9%. 
Table 3 shows the patient features, proportion of lung cancer patients identified and number of 
individuals needed to screen to detect one lung cancer patient using a variety of risk categories. Lung 
cancer patients had a higher mean predicted risk score compared with non-lung cancer cases in each 
category. Approximately 71% of the lung cancer patients had a predicted risk score of >2.5%. The 
number of individuals needed to screen to detect 1 cancer (NNS) ranged from 322 in individuals with 
a risk of <1% to 54 in individuals with a risk >5%. A risk threshold of >5% included 43.7% of lung cancers 
and 20% of the total cohort.  The corresponding figures for >2.5% and >1% were 70.8% of cancers and 
40.8% of the cohort, and 84.5% of cancers and 57.5% of the cohort. Setting a risk threshold of 1% gives 
a  NNS of 80, but would still miss 15.6% of the lung cancer cases, chiefly those with a younger median 
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age (56 years) and shorter duration of smoking (all ≤40 years duration). However, 43.5% of the cohort 
would not need to be screened 
PLCOm2012  
We identified 7,876 lung cancer events that took place in the 6 years following PLCOm2012 risk 
assessment on 1st January 2009. After imputing missing BMI and smoking intensity values PLCOm2012 
produced a c-statistic of 0.679 (0.673 – 0.685) in CPRD data. Furthermore, even following recalibration 
of the model intercept (Figure 2) there was still poor calibration of PLCOm2012 in CPRD data.  The overall 
mean predicted risk for lung cancer patients by PLCOm2012 model in the cohort was 3.76%. Similar to 
LLPv2, PLCOm2012 under-predicted lung cancer cases at the lowest risk scores, followed by over 
prediction. 
Table 4 shows the patient features, proportion of lung cancer patients identified and number of 
individuals needed to screen to detect one lung cancer patient using a variety of risk thresholds. Using 
imputed data, if a PLCOm2012 risk-threshold of >1.51% were applied to the CPRD population, it would 
detect 48.6% of the total lung cancer cases, with a NNS of 52 (23.5% of the total cohort selected). 
Setting the risk threshold to 0.15% increases the NNS to 88 (72.8% total cohort). This misses 11.41% 
of lung cancer cases, predominantly those with the lowest smoking intensity or where smoking data 
were incorrectly recorded in CPRD (Table 4). However, 31.8% of people would not need to be 
screened. Those in the highest risk threshold group (>1.5%) had a higher median age (71 years vs 66 
years for <0.15%) and were more likely to be current smokers (63% vs 36% respectively). 







This is the first study to validate and recalibrate the LLPv2 and PLCOm2012 models using primary care 
data. After restricting the primarycare data to included only ever smokers aged 50 to 80 years, our 
work showed that discrimination was only moderate for both models and, following recalibration of 
the model intercept, there was still poor calibration of the PLCOm2012 model in CPRD. Both models 
showed under-prediction at low risk followed by an over-prediction of those at highest risk. The detail 
required to use these models in practice is considerable (particularly with regards to smoking data) 
and would require a face to face or telephone consultation in order to augment the data already held 
in primary care records. Using both models at the current suggested risk thresholds (>1.51% for 
PLCOm2012 and >2.5% or >5% for LLPv2) missed 51%, 29% and 56% of lung cancer cases respectively. 
This concerned largely those with younger median age and lower smoking duration for LLP. Those who 
were missed by PLCOm2012 at lower thresholds were less likely to have COPD and were more likely to 
be ex-smokers with lower smoking intensity. Both models showed higher AUCs in PLCO data, reflecting 
the wider spread of lung cancer risk (inclusion of never smokers). 
STRENGTHS AND LIMITATIONS 
This is the largest external validation of the LLPv2 and PLCOm2012 risk models in the literature and, to 
our knowledge, the first using primary care data. Data in CPRD are prospectively recorded at the time 
of consultation in primary care which minimises reporting and recall bias, however, the information 
relies on accurate coding and timely data entry in primary care. To minimise errors related to this, we 
only used data entered by practices after the practice met the CPRD data quality and completeness 
standard. This study has tested the risk models in a context outside of their intended use. Both models 
should be populated with data collected from a potential participant in screening.  Instead the study 
shows how the models perform in routinely collected primary care data. Therefore, one of the key 
limitations is the lack of detailed smoking data in CPRD. One could argue that this places the PCLOm2012 
model at a disadvantage in validation, as the primary risk factors which drive the model are age and 
 14 
detailed smoking history. However, one of the objectives of this piece of work was not only to validate 
and calibrate the models in primary care data, but also to look at the feasibility of running these 
models in routinely collected data to select patients for entry into screening. Smoking data in primary 
care are recorded at the time of registration at a surgery using a questionnaire or during face to face 
consultations. Many practices record smoking status at regular intervals as part of the Quality 
Outcome Framework.(28)  Studies looking at the validity of smoking records in electronic primary care 
data have shown that it is in line with that obtained from population surveys such as the Health Survey 
for England in terms of proportion of people who are current or ex-smokers in age categories. 
(29)Those with no recorded smoking status are likely to be never smokers or smokers who quit before 
the age of 30 years, so it is unlikely that we would be excluding or misclassifying a substantial number 
of eligible smokers by labelling these people as never smokers.(30-32) As smoking intensity is grouped 
into categories in CPRD we had to assign each participant a specific number of cigarettes smoked per 
day, which was largely in multiples of 5 or 10 (apart from trivial smokers). Work by Shiffman has shown 
that even when a contemporaneous smoking history is taken from a person it is prone to digit bias.(33) 
In his study, two thirds of participants asked about daily smoking consumption recorded smoking 
quantity in multiples of 10, suggesting that our approach is not unreasonable. The key drivers in these 
risk models are age, sex and smoking, so missing data on other predictor variables is less likely to 
impact the performance of the risk models.  Thus, although it is easy to criticise data completeness 
and accuracy in routinely collected primary care data, the reality is that it is often better than assumed. 
Therefore, using these data has to be balanced against the extra cost of directly-acquired data which 
itself may be subject to incompleteness and bias. 
Recently the LLPv2 risk model and a recalibrated version (LLPv3) have been validated and calibrated 
using questionnaire data from the 75,958 UKLS individuals who responded to the first approach 
questionnaire and have been followed up for lung cancer for over 5 years(34). This cohort included 
never smokers (47%). The authors found the AUC to be 0.81 for both LLPv2 and LLPv3 but LLPv2 was 
found to overestimate the absolute risk approximately two fold. The LLPv3, which was calibrated to 
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contemporary English incidence, achieved substantially more accurate prediction of absolute 
incidence, and would now be an appropriate update to LLPv2 in selecting a high-risk group for screening 
in the UK. 
 
OTHER WORK IN THE LITERATURE 
A study by Li et al (16) compared the performance of four risk prediction models including LLP and 
PLCOm2012 in 20,700 German participants of the European Prospective Investigation into Cancer and 
Nutrition cohort. This showed better discrimination  for  the PLCOm2012 model (c-index 0.81, 95% CI 
0.76 – 0.86) compared with the LLP model (c-index 0.79, 95% 0.73 – 0.83). However, the cohort had 
an overall rate of lung cancer of less than 0.5% with fewer than 100 lung cancer events.  
Weber et al (35) externally validated PLCOm2012 in a cohort of 95,882 Australian ever-smokers aged 45 
years and older. They used questionnaire data completed as part of the 45 and Up Study (36), linked 
to a number of population datasets. They demonstrated an AUC of 0.80 (95% CI, 0.78–0.81) with good 
calibration in their population (mean and 90th percentile absolute difference between observed and 
predicted probabilities of 0.006 and 0.016, respectively). The authors assessed the model 
performance at a risk threshold of 1.51% and showed a sensitivity of 70% (95% CI 67.1–72.7) and 
specificity of 75.4% (95% CI 75.2–75.7). In a subset of the population (those aged 55-74 years) they 
also assessed a variety of additional risk thresholds, namely 1.49%, 1.73% and 2% but did not show 
that changing the risk threshold made a substantial improvement to the sensitivity and specificity. The 
45 and Up Study cohort may be more similar to those who participate in trials, from which PLCOm2012 
was derived, as people had to personally complete a questionnaire, consent form and mail it to the 
Study centre to be included. As the authors acknowledge, this means that there may be a selection 
bias in favour of less deprived people. The good calibration suggests that the population is similar to 
that from which the model was derived. The data required to compute the risk score, particularly with 
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regards to detailed smoking data, were largely derived from these questionnaires rather than already 
available in routinely collected data.    
Ten Haaf et al (6) conducted a retrospective validation of 9 risk prediction models using data from 
NLST and PLCO. Both calibration and discriminative ability was better for all models using PLCO data 
than NLST. PLCOm2012 showed better discrimination than LLP (0.789 (95% CI 0.781-0.797) vs 0.745 (95% 
CI 0.736-0.755) in the PLCO control arm) but the PLCOm2012 was derived from this dataset which places 
PLCOm2012 at an advantage compared with LLPv2. Interestingly, most of the models tested in this study 
had greater discriminative ability in predicting 6-year lung cancer mortality rather than 6-year lung 
cancer incidence.  
Katki et al (9) evaluated 9 risk prediction models in US data on ever smokers from the National 
Institutes of Health–AARP Diet and Health Study (NIH-AARP) and the Cancer Prevention Study II 
Nutrition Survey (ACS CPSII) cohort to compare model performance. Both LLP and PLCOm2012 
showed some overestimation of risk but PLCOm2012 was better calibrated in this cohort. Both 
showed moderate discrimination; PLCOm2012 with AUC of 0.769 (95% CI 0.766-0.772) and 0.754 (95% 
CI 0.741-0.767) for NIH-AARP and ACS CPSII respectively and LLP with AUC values of 0.726 (95% CI 
0.722-0.731) and 0.726 (95% CI 0.711-0.740)) respectively. When the authors set screening eligibility 
at 2% lung cancer risk over 5 years the well calibrated models, including PLCOm2012 selected fewer 
participants for inclusion (ranges between 7.6-10.9 million, compared with 14.5-26 million for the less 
well calibrated models). 
CLINICAL RELEVANCE AND CONCLUSIONS 
Primary care records in the UK are likely to be used to identify those who may be eligible for CT 
screening because they provide an efficient way to identify ever-smokers and thus minimise contact 
with people who would not be eligible and reduce cost and potential distress from being contacted 
about cancer screening when there is no benefit. Other countries, where similar data exist will likely 
do the same. Ideally, a model with good sensitivity and specificity should be applied directly to primary 
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care data and only then would potential participants be contacted. We have shown that two existing 
models, even at very low risk thresholds, would miss a significant number of people if applied in this 
way. We do not know how much better the models perform when applied in the lower risk categories 
to more detailed, directly-derived data from participant questionnaires but it is likely that a significant 
proportion of people who develop cancer would be below the threshold. If models are to be used to 
derive a first-step “enriched” population, then the second step would likely involve increasing the risk 
threshold to comply with cost-effectiveness standards. The principle of the two-step approach is the 
use of an initial model at a low risk threshold in order to maximise sensitivity, with a second model 
that uses the integrity of detailed and directly-acquired data to improve specificity and reduce cost. 
This study has tested models at different thresholds and we conclude that specificity in the first step 
of the two-step approach would only be improved by obtaining more accurate data to use in the risk 
prediction, or by the development of new models. Obtaining better data in a first step approach could 
place a considerable burden on services with limited gain and extra cost. However, once national 
screening programmes are in place, this could be the subject of data quality improvement in primary 
care, with additional data fields completed that are important in risk prediction e.g. detail of family 
history. It will be important to compare the performance of two-step approaches with newer, single 
step models developed in primary care data.  The main value of improved models is in identifying 
those who are at lower or intermediate risk on the basis of current risk models, but who arguably may 
have more life-years to gain from screening due to younger age, lower smoking intensity and 
consequently fewer co-morbidities.  It is key that future risk prediction models are able to predict not 
only eligibility for entry into screening but also whether, and by how much, participants can expect to 
benefit. Some studies have suggested that risk models may identify those who are less likely to benefit 
from screening due to competing causes of mortality and morbidity.(37) Optimal risk thresholds need 
to be identified based on local population data and further work is needed to determine what the best 
strategy is for identifying and inviting those who have most to gain from screening for lung cancer. 
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In conclusion, two validated multivariable models perform less well than previously reported when 
applied to routinely collected primary care data restricted to ever smokers aged 50 to 80 years, which 
may be explained by the quality and completeness of the data.  However, they may be used as a way 
to reduce the total number of people in this higher risk group who are contacted as part of a screening 
programme by a third to a half but with 10-15% of people who develop lung cancer excluded from 
more detailed evaluation. Whilst many of these excluded people may not be at high enough risk to be 
eligible, further work is needed to establish how many are incorrectly excluded and to what extent 
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Table 1 (a): CPRD cohort and original LLP cohort demographic comparison  
†Variables only in LLPV2 model – excluded from CPRD analysis. *Original LLPV2 model uses Exposure to Asbestos 
  CPRD LLPV2 
  Cohort (n=842,109) Percent or interquartile range in parentheses 
Cohort (n=1736) 
Percent or interquartile range in parentheses 
  Non Lung cancer cases Lung cancer cases Controls Cases 
Number of patients 834986 (99.1) 7123 (0.9) 1157 (67) 579 (33) 
Sex         
Females 373255 (45) 3060 (43) 444 (38) 222 (38) 
Males 461731 (55) 4063 (57) 713 (62) 357 (62) 
Age 62 (56 – 70) 69 (63 – 74) 66 (57 – 75) 66 (57 – 75) 
Pneumonia         
No 811244 (97.2) 6789 (95.3) 989 (86) 361 (62) 
Yes 23742 (2.8) 334 (4.7) 168 (14) 104 (18) 
Personal History        
No 834770 (99.9) 7116 (99.9) 1091 (94) 509 (88) 
Yes 216 (0.03) 7 (0.1) 66 (6) 72 (12) 
Family History         
No 834151 (99.9) 7115 (99.9) 947 (82) 456 (79) 
Yes 835 (0.1) 8 (0.1) 62 (5) 46 (8) 
Late onset (>=60 years)†  -  - 148 (13) 77 (13) 
Asbestosis*         
No 831734 (99.6) 7065 (99.2) 664 (76) 287 (65) 
Yes 3252 (0.4) 58 (0.8) 206 (24) 155 (35) 
Smoking Duration         
Never†     335 (29) 27 (5) 
<=20 years 133770 (14) 266 (4) 236 (20) 43 (7) 
>20- ≤40 years 392089 (47) 1985 (28) 337 (29) 157 7) 
>40- ≤60 years 320646 (38) 4653 (65) 234 (20) 321 (55) 
>60 years 8481 (1) 219 (3) 15 (1) 31 (5) 
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Table 1 (b): CPRD cohort and PLCOm2012 cohort demographic comparison 
 
  CPRD NLST PLCOm2012 
  Cohort (n=842,109) CT Arm (n=26,722) 
Chest x-ray arm 
(n=26,730) 




































Number of patients 834233 (99.1) 7876 (0.9) 
25692 
(96) 1030 (4) 25835 (97) 895 (3) 39846 (98) 754 (2) 
39363 
(98) 709 (2) 
Age 62 (56 – 70) 68 (62 – 74) 
60 (57 – 
65) 
63 (59 – 
68) 60 (57 – 65) 
64 (60 – 
68) 62 (58 – 66) 
65 (60 – 
69) 




BMI 27 (24 – 30.5) 
26 (23 – 
30) 
27 (24 – 
31) 
26 (24 – 
29) 
27 (24.5 – 
31) 
26 (24 – 
29) 27 (24 – 30) 
26 (23 – 
29) 
27 (24 – 
30) 
26 (23 – 
29) 
Missing BMI n (%) 83260 (10) 721 (9) 146 (1) 13 (1) 206 (1) 7 (1) 494 (1) 10 (1) 742 (2) 15 (2) 
Personal History               




(96) 956 (93) 24554 (95) 833 (93) 38033 (95) 709 (94) 
37532 
(95) 653 (92) 
Yes 216 (0.03) 7 (0.1) 1028 (4) 68 (7) 1154 (4) 58 (6) 1813 (5) 45 (6) 1831 (5) 56 (8) 
Missing 0 (0) 0 (0) 76 (0) 6 (1) 127 (0.5) 4 (1) 0 (0) 0 (0) 0 (0) 0 (0) 
Family History               




(77) 746 (72) 19812 (77) 640 (72) 33718 (85) 565 (75) 
33485 
(85) 541 (76) 
Yes 834 (0.1) 9 (0.1) 5554 (22) 261 (25) 5570 (22) 236 (26) 4514 (11) 139 (18) 4414 (11) 130 (18) 
Missing 0 (0) 0 (0) 397 (2) 23 (2) 453 (2) 19 (2) 1614 (4) 50 (7) 1464 (4) 38 (5) 
COPD               
No 775255 (93) 6122 (78) 21283 (83) 765 (74) 21435 (83) 643 (72) 36381 (91) 602 (80) 
35899 
(91) 567 (80) 
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Yes 58978 (7) 1754 (22) 4409 (17) 265 (26) 4400 (17) 252 (28) 3465 (9) 152 (20) 3464 (9) 142 (20) 
Smoking Status               
Ex 473551 (57) 3633 (46) 1350 (53) 429 (42) 13561 (52) 337 (38) 32102 (81) 422 (56) 
31708 
(81) 385 (54) 
Current 360682 (43) 4243 (54) 12183 (47) 601 (58) 12274 (48) 558 (62) 7744 (19) 332 (44) 7655 (19) 324 (46) 
Smoking Intensity (cig/d) 15 (7 – 24) 17 (9 – 27) 25 (20 – 35) 
30 (20 – 
40) 
25 (20 – 
30.5) 
25 (20 – 
40) 20 (10 – 30) 
30 (20 – 
40) 
20 (10 – 
30) 
30 (20 – 
40) 
Missing Smoking Intensity 
n (%) 231508 (28) 1212 (15) 0 (0) 0 (0) 0 (0) 0 (0) 78 (0.2) 4 (0.5) 112 (0.3) 2 (0.3) 
Smoking Duration 37 (30 – 45) 45 (38 – 52) 
40 (35 – 
44) 
44 (40 – 
49) 40 (35 – 44) 
44 (40 – 
49) 28 (16 – 39) 
42 (35 – 
48) 
28 (16 – 
39) 
42 (35 – 
47) 
Quit Years* 9 (6 – 24) 10 (5 – 15) 7 (3 – 11) 5 (2 – 10) 7 (3 – 11) 6 (2 – 11) 20 (10 – 30) 10 (4 – 19) 
20 (10 – 




Table 2: AUC 
  CPRD NLST PLCO 
  Cohort CT arm Chest x-ray arm Chest x-ray arm Control arm 
LLPV2* 0.700 (0.694 – 0.710) 0.66 (0.64 – 0.67) 0.68 (0.67 – 0.69) 0.75 (0.74 – 0.76) 0.75 (0.74 – 0.76) 
PLCOm2012† 0.679 (0.673 – 0.685) 0.69 (0.68 – 0.70) 0.71 (0.70 – 0.72) 0.80 (0.79 – 0.81) 0.79 (0.78 – 0.80) 
* Five year incidence model performance 
† Six year Model performance 
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Table 3: LLPV2 (recalibrated) performance in CPRD showing the proportion of people with lung cancer that might have been screened at selected thresholds 
  LLPV2 (recalibrated) performance in CPRD  
Corresponding risk threshold <1% (n=357,595) 1% - <2.5% (n=140,646) 2.5% - <5% (n=174,985) ≥5% (n=168,883) 
















Number of patients 356485 (99.7) 1110 (0.3) 
139672 
(99.3) 974 (0.7) 
173057 
(98.9) 1928 (1.1) 
165772 
(98.2) 3111 (1.8) 
Mean predicted risk 0.56% 0.64% 1.62% 1.69% 3.64% 3.71% 7.10% 7.50% 
Proportion of total Lung Cancer 15.6% 13.7% 27.1% 43.7% 
Need to Screen to detect 1 lung 
cancer case 322 144 91 54 
Sex                 
Females 178059 (50) 598 (54) 55285 (40) 454 (47) 78656 (45) 923 (48) 61255 (37) 1085 (35) 
Males 178426 (50 512 (46) 84387 (60) 520 (53) 94401 (55) 1005 (52) 104517 (63) 2026 (65) 
Age 55 (52 – 58) 56 (53 – 58) 65 (61 – 71) 66 (61 – 70) 65 (62 – 68) 65 (63 – 68) 73 (71 – 77) 74 (71 – 77) 
Pneumonia                 
No 352184 (98.8) 1097 (98.8) 
133567 
(95.6) 935 (96) 
169776 
(98.1) 1887 (97.9) 
155717 
(93.9) 2870 (92.2) 
Yes 4301 (1.2) 13 (1.2) 6105 (4.4) 39 (4) 3281 (1.9) 41 (2.1) 10055 (6.1) 241 (7.8) 
Personal History         
No 356463 (99.9) 1110 (100) 
139636 
(99.9) 974 (100) 
173026 
(99.9) 1925 (99.8) 
165645 
(99.9) 3107 (99.9) 
Yes 22 (0.01) 0 (0) 36 (0.03) 0 (0) 31 (0.02) 3 (0.2) 127 (0.1) 4 (0.1) 
Family History         
No 356094 (99.9) 1109 (99.9) 
139513 
(99.9) 973 (99.9) 
172917 
(99.9) 1924 (99.8) 
165627 
(99.9) 3109 (99.9) 
Yes 391 (0.1) 1 (0.1) 159 (0.1) 1 (0.1) 140 (0.1) 4 (0.2) 145 (0.1) 2 (0.1) 
Asbestosis         
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No 356270 (99.9) 1110 (100) 
139036 
(99.5) 973 (99.9) 
172489 
(99.7) 1916 (99.4) 
163939 
(98.9) 3066 (98.6) 
Yes 215 (0.1) 0 (0) 636 (0.5) 1 (0.1) 568 (0.3) 12 (0.6) 1833 (1.1) 45 (1.4) 
Smoking Duration                 
<=20 years 90384 (25) 164 (15) 22885 (16) 94 (10) 494 (0.3) 7 (0.4) 7 (0) 1 (0) 
>20- ≤40 years 266101 (75) 946 (85) 100929 (72) 749 (77) 23906 (14) 269 (14) 1153 (1) 21 1) 
>40- ≤60 years 0 (0) 0 (0) 15858 (12) 131 (13) 148657 (86) 1652 (86) 156131 (94) 2870 (92) 




Table 4: PLCOm2012 (recalibrated) performance in CPRD showing the proportion of people with lung cancer that might have been screened at selected 
thresholds 
  PLCOm2012 performance in CPRD  
Corresponding risk threshold <0.15% (n=229,443) 0.15% - 1.51% (n=414,032) >1.51% (n=198,634) 
  Non Lung cancer cases 
Lung cancer 
cases 








Number of patients 288544 (99.6) 899 (0.4) 410881 (99.2) 3151 (0.8) 194808 (98.1) 3826 (1.9) 
Mean predicted risk  0.047%  0.045%  0.63% 0.74%  3.90%  4.76%  
Proportion of total Lung Cancer 11.41% 40.01% 48.58% 
Need to Screen to detect 1 lung cancer 
case 255 131 52 
Age 60 (54 - 66) 66 (59 - 73) 61 (55 - 67) 65 (59 - 72) 69 (64 - 74) 71 (66 - 75) 
BMI 27.3 (24.3 – 30.9) 27 (23.8 – 30.7) 27 (24 - 30.6) 
26.3 (23.2 - 
29.9) 26.2 (23.2 - 29.5) 25.6 (22.6 - 29) 
Personal History             
No 228477 (99.9) 898 (99.9) 410815 (99.9) 3148 (99.9) 194725 (99.9) 3823 (99.9) 
Yes 67 (0.03) 1 (0.1) 66 (0.02) 3 (0.1) 83 (0.04) 3 (0.1) 
Family History             
No 228317 (99.9) 898 (99.9) 410513 (99.9) 3146 (99.8) 194569 (99.9) 3823 (99.9) 
Yes 227 (0.1) 1 (0.1) 368 (0.1) 5 (0.2) 239 (0.1) 3 (0.1) 
COPD             
No 221911 (97.1) 772 (85.9) 389474 (94.8) 2617 (83.1) 163870 (84.1) 2733 (71.4) 
Yes 6633 (2.9) 127 (14.1) 21407 (5.2) 534 (16.9) 30938 (15.9) 1093 (28.6) 
Smoking Status             
Ex 164008 (71.8) 573 (63.7) 231246 (56.3) 1592 (50.5) 78297 (40.2) 1468 (38.4) 
Current 64536 (28.2) 326 (36.3) 179635 (43.7) 1559 (49.5) 116511 (59.8) 2358 (61.6) 
Smoking Intensity (cig/d) 5 (2 - 8) 2 (2 - 6) 16 (11 - 25) 13 (8 - 19) 24 (17 - 33) 24 (16 - 33) 
Smoking Duration (in years) 32 (18 - 39) 38 (31 - 45) 35 (29 - 42) 41 (34 - 48) 47 (42 - 52) 49 (44 - 54) 




Figure 1: LLPV2 
 
LLPV2 external validation in CPRD cohort intercept only (<5% risks) 
Figure 2: PLCOm2012  
 
  
PLCOm2012 external validation in CPRD cohort intercept (<3% risks) 
 
